文献速递白血病造血干细胞移植与细胞治疗

如何治疗难治性和复发性急性髓系白血病

How I treat refractory and relapsed acute myeloid leukemia.
PubMed 文献 · Blood · 2024-01-01

多数急性髓系白血病(AML)患者即使接受新型靶向治疗仍会出现难治/复发(R/R)疾病。本文综述R/R AML的治疗策略,强调临床试验应为首选、异基因造血细胞移植(HCT)是唯一可能治愈手段,并讨论以可测量残留病(MRD)触发治疗、挽救化疗或靶向治疗桥接HCT,以及FLT3、IDH1/2突变和AZA/VEN失败后的靶向治疗与在研方案。

要点

  • R/R AML治疗选择受疾病生物学复杂性和前线治疗差异影响,临床试验应为首要优先。
  • 异基因HCT是多数R/R AML患者唯一可能治愈的策略。
  • 以MRD触发治疗(包括异基因HCT)已用于预防明显血液学复发。

核心结论

  • R/R AML即使有新型和靶向治疗仍常见,临床试验入组应为首要优先。
  • 异基因HCT是多数R/R AML患者唯一可能治愈的策略。
  • 以MRD触发的治疗(包括异基因HCT)已用于预防明显血液学复发。
  • AZA/VEN后R/R患者结局黯淡,现有靶向治疗结果亦不满意。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 多数AML患者即使接受新型和靶向治疗仍发生难治/复发疾病。
  • R/R AML的获批治疗仅覆盖部分亚组,临床试验应为首要优先。
  • 挽救化疗或靶向治疗常在HCT前给药以降低白血病负荷。
  • AZA/VEN后R/R患者结局黯淡,现有靶向治疗结果不满意。
  • 在研方向包括menin抑制剂(用于NPM1突变或KMT2A重排)、靶向CD47的抗体及含AZA/VEN的三联方案;后者骨髓抑制作用显著,找到合适方案和剂量具有挑战性。

关键数值与推荐

  • 吉瑞替尼获FDA和EMA批准用于FLT3突变复发AML。
  • IDH1/2突变复发AML的靶向治疗仅获FDA批准。
  • menin抑制剂为NPM1突变或KMT2A重排患者的靶向治疗。
  • 靶向CD47的抗体为靶向巨噬细胞免疫检查点的抗体。

临床怎么用

  • 临床试验入组应为首要优先。
  • 异基因HCT是多数患者唯一可能治愈的策略。
  • 可在HCT前给予挽救化疗或靶向治疗以降低白血病负荷。
  • 可按MRD触发治疗(包括异基因HCT)以预防明显血液学复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with acute myeloid leukemia (AML) develop refractory/relapsed (R/R) disease even in the presence of novel and targeted therapies. Given the biological complexity of the disease and differences in frontline treatments, there are therapies approved for only subgroups of R/R AML, and enrollment in clinical trials should be first priority. Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative strategy for most patients. Therapeutic approaches, including allogeneic HCT, triggered by the presence of measurable residual disease (MRD), have recently evolved to prevent overt hematologic relapse. Salvage therapy with chemotherapy or targeted therapy is frequently administered before HCT to reduce the leukemic burden. Gilteritinib is approved by the Food and Drug Administration and European Medicines Agency for patients with relapsed FLT3 mutated AML, whereas targeted therapy for relapsed IDH1/2 mutated AML has only FDA approval. Patients who are R/R after azacitidine and venetoclax (AZA/VEN) have a dismal outcome. In this setting, even available targeted therapies show unsatisfactory results. Examples of ongoing developments include menin inhibitors, a targeted therapy for patients with mutated NPM1 or KMT2A rearrangements, antibodies targeting the macrophage immune checkpoint CD47, and triple combinations involving AZA/VEN. The latter cause significant myelosuppressive effects, which make it challenging to find the right schedule and dose.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thol F, Döhner H, Ganser A, et al. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024. PMID: 37944143. doi:10.1182/blood.2023022481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。